title: Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
abstract: Canine parvovirus disease is an acute infectious disease caused by canine parvovirus (CPV). Current commercial vaccines are mainly attenuated and inactivated; as such, problems concerning safety may occur. To resolve this problem, researchers developed virus-like particles (VLPs) as biological nanoparticles resembling natural virions and showing high bio-safety. This property allows the use of VLPs for vaccine development and mechanism studies of viral infections. Tissue-specific drug delivery also employs VLPs as biological nanomaterials. Therefore, VLPs derived from CPV have a great potential in medicine and diagnostics. In this study, small ubiquitin-like modifier (SUMO) fusion motif was utilized to express a whole, naturalVP2 protein of CPV in Escherichia coli. After the cleavage of the fusion motif, the CPV VP2 protein has self-assembled into VLPs. The VLPs had a size and shape that resembled the authentic virus capsid. However, the self-assembly efficiency of VLPs can be affected by different pH levels and ionic strengths. The mice vaccinated subcutaneously with CPV VLPs and CPV-specific immune responses were compared with those immunized with the natural virus. This result showed that VLPs can effectively induce anti-CPV specific antibody and lymphocyte proliferation as a whole virus. This result further suggested that the antigen epitope of CPV was correctly present on VLPs, thereby showing the potential application of a VLP-based CPV vaccine.
authors.affiliation: State Key Laboratory of Veterinary Etiological Biology and National Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, Lanzhou, Gansu, 730046, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Xu
authors.forename: Hui-Chen
authors.initials: HC
authors.lastname: Guo
authors.forename: Yan-Quan
authors.initials: YQ
authors.lastname: Wei
authors.forename: Hu
authors.initials: H
authors.lastname: Dong
authors.forename: Shi-Chong
authors.initials: SC
authors.lastname: Han
authors.forename: Da
authors.initials: D
authors.lastname: Ao
authors.forename: De-Hui
authors.initials: DH
authors.lastname: Sun
authors.forename: Hai-Ming
authors.initials: HM
authors.lastname: Wang
authors.forename: Sui-Zhong
authors.initials: SZ
authors.lastname: Cao
authors.forename: Shi-Qi
authors.initials: SQ
authors.lastname: Sun
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D036022:Capsid Proteins / Q000235:genetics / Q000378:metabolism*; D049109:Cell Proliferation; D004283:Dog Diseases / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D004285:Dogs; D004926:Escherichia coli / Q000235:genetics; D015870:Gene Expression; D007279:Injections, Subcutaneous; D008214:Lymphocytes / Q000276:immunology; D051379:Mice; D010322:Parvoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D017993:Parvovirus, Canine / Q000235:genetics / Q000276:immunology*; D055503:Protein Multimerization; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D014611:Vaccination / Q000379:methods; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D058425:Vaccines, Virus-Like Particle / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification
chemical_list: D000914:Antibodies, Viral; D036022:Capsid Proteins; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D058425:Vaccines, Virus-Like Particle; D014765:Viral Vaccines